DOD Biotech Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was THB 492.6 million compared to THB 458.37 million a year ago. Revenue was THB 521.42 million compared to THB 466.95 million a year ago. Net loss was THB 1.63 million compared to THB 36.98 million a year ago. Basic earnings per share from continuing operations was THB 0.02 compared to THB 0.034 a year ago. Diluted earnings per share from continuing operations was THB 0.02 compared to THB 0.034 a year ago. Basic loss per share was THB 0.004 compared to THB 0.09 a year ago. Diluted loss per share was THB 0.004 compared to THB 0.09 a year ago.